Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | ASPH | Q12797 | 3/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22609318 | 0.85 | MEN1 (0.51) | KMT2AKDM4ELMNAMAPTNPC1 | |
| SCHEMBL22609275 | 0.76 | NPC1 (0.41) | KMT2AKDM4ELMNANPC1 | |
| SCHEMBL22609253 | 0.76 | ALDH1A1 (0.52) | P4HTMKMT2APPARAASPHKDM8 | |
| SCHEMBL23453709 | 0.71 | P4HTM (0.47) | P4HTMKMT2APPARASTING1LMNA | |
| SCHEMBL15528783 | 0.69 | KMT2A (0.56) | P4HTMKMT2APPARAASPHKDM8 | |
| SCHEMBL22609297 | 0.67 | P4HTM (0.48) | P4HTMKMT2APPARAASPHKDM8 | |
| SCHEMBL8742119 | 0.66 | PPARA (0.58) | P4HTMKMT2APPARASTING1CYP1A2 | |
| SCHEMBL22609276 | 0.66 | ALDH1A1 (0.53) | KMT2AMAPTTSHR | |
| SCHEMBL19422692 | 0.66 | P4HTM (0.53) | P4HTMKMT2APPARAASPHKDM8 | |
| SCHEMBL2553685 | 0.65 | HTT (0.65) | KMT2ALMNANPC1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3731840-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | Orfan Biotech Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | P4HTM 1453/4885KMT2A 3407/4885PPARA 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.